Dai Zheng-Yan, Li Yu-Ting, Lin Jin-Yi, Liu Chien-Lin, Tsou Yung-An, Lin Chia-Der, Tai Chih-Jaan, Shih Liang-Chun
Department of Otorhinolaryngology-Head and Neck Surgery, China Medical University Hospital, Taichung 404327, Taiwan.
Department of Otorhinolaryngology-Head and Neck Surgery, Asia University Hospital, Taichung 404327, Taiwan.
J Clin Med. 2025 May 22;14(11):3637. doi: 10.3390/jcm14113637.
Although upper and lower respiratory tract diseases coexist, studies discussing the relationship between chronic rhinitis (CR) and chronic obstructive pulmonary disease (COPD) are limited. Fluticasone nasal sprays are common treatment options for patients with rhinitis. Therefore, we aimed to investigate the effects of fluticasone nasal spray on patients with both CR and COPD. : A retrospective review was performed using data from former smokers with CR and COPD at China Medical University Hospital (CMUH). Based on their medication history, patients were allocated into Group A, who had received treatment with fluticasone nasal spray, and Group B, who had never received this treatment. Pulmonary function test results, including forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC), were collected for both groups before treatment and one year after treatment. Statistical analysis was performed to evaluate the impact of fluticasone nasal spray treatment on pulmonary function. : A total of 123 former smokers were included, with 62 patients in Group A and 61 patients in Group B. At baseline, there was no significant difference in age, sex, and pulmonary function between the two groups. After one year of treatment, Group A showed an upward trend in pulmonary function, with the FEV1 increasing from 1.613 ± 0.554 to 1.708 ± 0.675 ( < 0.05) and the FVC increasing from 2.540 ± 0.694 to 2.670 ± 0.839 ( < 0.05). On the other hand, Group B exhibited a downward trend in pulmonary function after one year, with the FEV1 decreasing from 1.609 ± 0.554 to 1.544 ± 0.517 ( < 0.05) and the FVC decreasing from 2.586 ± 0.665 to 2.495 ± 0.679 ( < 0.05). : This retrospective study suggests that the combined use of fluticasone nasal spray may be associated with improved pulmonary function in former smokers with both CR and COPD. This finding supports the concept of "united airway disease".
尽管上呼吸道疾病和下呼吸道疾病并存，但探讨慢性鼻炎（CR）与慢性阻塞性肺疾病（COPD）之间关系的研究有限。氟替卡松鼻喷雾剂是鼻炎患者常用的治疗选择。因此，我们旨在研究氟替卡松鼻喷雾剂对CR合并COPD患者的影响。：利用中国医科大学附设医院（CMUH）前吸烟者中CR合并COPD患者的数据进行回顾性分析。根据用药史，将患者分为A组（接受过氟替卡松鼻喷雾剂治疗）和B组（从未接受过该治疗）。收集两组患者治疗前及治疗一年后的肺功能测试结果，包括一秒用力呼气容积（FEV1）和用力肺活量（FVC）。进行统计分析以评估氟替卡松鼻喷雾剂治疗对肺功能的影响。：共纳入123名前吸烟者，A组62例，B组61例。基线时，两组患者的年龄、性别和肺功能无显著差异。治疗一年后，A组肺功能呈上升趋势，FEV1从1.613±0.554增至1.708±0.675（P<0.05），FVC从2.540±0.694增至2.670±0.839（P<0.05）。另一方面，B组治疗一年后肺功能呈下降趋势，FEV1从1.609±0.554降至1.544±0.517（P<0.05），FVC从2.586±0.665降至2.495±0.679（P<0.05）。：这项回顾性研究表明，在CR合并COPD的前吸烟者中，联合使用氟替卡松鼻喷雾剂可能与肺功能改善有关。这一发现支持了“联合气道疾病”的概念。
